Tag:

Epizyme

Latest Headlines

Latest Headlines

The top 10 biotech IPOs of 2013

Last year when we did the list of the top 10 biotech IPOs of 2012, we were lucky to have 10. Actually, there were 11, and that looked pretty good compared to the lean and hungry years of 2008 to...

UPDATED: Fresh burst of biotech IPO pitches launches a busy Q4 season

After a slight lull in the biotech IPO arena, new offerings came barreling back this week with some fresh breakouts. In particular Foundation Medicine priced over the range and immediately soared more than 80%. And Ophthotech also crested its range, erasing any lingering doubts about the short-term sustainability of the biotech IPO frenzy. Together they raised $273 million in a 24-hour pop. Read the report >>

Epizyme picks up FDA orphan nod for lead cancer drug as going public pays off

The drug is in a Phase I clinical trial that began in September 2012. Its shares rose nearly 1% this morning to $31.44 per share, which is more than double the IPO price of $15 per share set on May 31.

In hot biotech market, personalized drugs rise to the top

Investor interest in biotech is enjoying a prosperous comeback, leading industry watchers and journalists to seek reasons for the frenzy. In The New York Times ' DealBook post, one of the recurring themes among the high-flying drug developers, was a focus on personalized medicine.

The biotech IPO scene turns red hot

During all of last year there were only 11 biotech IPOs. But even that weak number looked pretty good compared to the barren years leading away from the 2008 financial crisis. In the last 6 months, though, the industry has seen a tremendous rebound, with almost twice that number of IPOs in half the time. And there's no sign that the great leap into the public market is waning, with 10 more IPOs in the queue. Read the full report >>

UPDATED: Epizyme scores latest biotech IPO victory to advance cancer pipeline

The Cambridge, MA-based developer of targeted cancer drugs sold about 5.9 million shares for $15 per share, hitting the high end of its proposed $13-$15 per share price range and exceeding previous fundraising targets for the offering.

Epizyme hits the biotech IPO queue with rapid R&D plan for cancer drugs

The Cambridge, MA-based biotech company has proposed to raise up to $69 million in a public debut, with plans to spend proceeds from the deal on advancing clinical trials for its top candidates against cancer-related epigenetic enzymes.

Abbott aids biotech Epizyme in matching epigenetic drug with cancer patients

The agreement follows the start of a Phase I study of the compound, EPZ-5676, for which biotech giant Celgene has partnered with the startup for development outside the U.S.

Kleiner Perkins to back early-stage biotechs with $525M fund

Kleiner Perkins Caulfield & Byers has closed the books on a new $525 million fund. And a chunk of that treasure is earmarked for early-stage life science companies.

Epizyme builds epigenetics lineup with $90M Celgene score

The pact includes a commitment to pay tens of millions more in milestones for any successful therapies that come out of the deal.